«Schools for Patients» with Urolithiasis and Prostatic Diseases

Improvement of patients` knowledge about their disease is an important part of management of chronic diseases. One of the effective methods to increase the level of medical education of the population is to hold regular meetings with patients within the framework of «schools for patients». Urolithiasis is one of the most common urological diseases (3.5‒9.6% of the population). In addition to its high prevalence, Urolithiasis has a high recurrence rate (50‒75% over 5‒10 years). The most common prostate diseases are prostatitis, benign hyperplasia, and cancer. These diseases have a chronic course and require а long-term observation. Treatment of urolithiasis and prostatic diseases is one of the priority fields for the urology department of the Pavlov First St. Petersburg State Medical University. In addition to surgical treatment, the specialists of urology department take measures aimed at prevention of recurrence and complications of these diseases. Schools for patients with urolithiasis and prostate diseases are held every 3 months. The topics for discussion are chosen by the patients themselves. In addition to reports, patients undergo ultrasound of the kidneys, bladder and prostate, as well as consultations. Participation in schools of patients creates a conscious attitude to their disease, increases adherence to treatment and improves the prognosis of the disease. The distribution of such programs corresponds to the modern concept of preventive medicine and increases the efficiency of providing medical care to the population.

1. Рonomareva I.P., Рrashchayeu K.I., Ilnitsky A.N. School model patient in palliative care geriatrics: a new look at the problem. The Russian Archives of Internal Medicine. 2016;6(4):42‒46. (In Russ.). https://doi.org/10.20514/2226-6704-2016-6-4-42-46

2. Zlobin A.A., Smirnov S.V., Onufrieva M.S., Stepanova E.Ju., Rukavishnikov M.V., Balakirev V.P., Kuz’min A.I., Kosheleva N.A. Practical guide to the organization of social services for patients with HIV infection (using the experience of “patient Schools”). Moscow: Extreme Design Studio; 2011:7‒32. (in Russ.). ISBN: 978-5-9902955-1-3

3. Kuznetsov A., Kashina E., Lazareva L., Kichatova E., Gerasimova O., Muntyan I. School of health for patients with type 2 diabetes. Proceedings of the Samara scientific center of the Russian Academy of sciences. 2014;16(5-4):1511‒1513. (in Russ.). eLIBRARY ID: 23401290

4. Polevaya O.A., Karabinenko A.A. School of health for patients with bronchial asthma. Medical case. 2007;(3):42‒44. (in Russ.). eLIBRARY ID: 15123508

5. Kontsevaja A.V., Kalinina А.М., Spivak E.J. Influence of Health School training of patients with ischemic heart disease on pharmacotherapy profile and cost (АВС/VEN analysis). State Research Center of Preventive Medicine of Rosmedtechnology. 2008;4(3):59‒64. (in Russ.). eLIBRARY ID: 11585840

6. Kontsevaya A.V., Spivak E.Y., KalininaA.M. Social and economic efficiency of health schools for patients with ihd in primary health care. Effective pharmacotherapy. 2011;(12):92‒97. (in Russ.). eLIBRARY ID: 21651265

7. Karpova I.P., Shilnikova N F. Estimation of the effectiveness of the activity of the profile school of arterial hypertension. Far East Medical Journal. 2011;(3):13‒15. (in Russ.). eLIBRARY ID: 16755439

8. Curhan G. Epidemiology of Stone Disease. Urolclin North Am. 2007;34(3):287–293. https://doi.org/10.1016/j.ucl.2007.04.003

9. Lieske JC, Pena de la Vega LS, Slezak JM, Bergstralh EJ, Leibson CL, Ho KL, Gettman MT. Renal stone epidemiology in Rochester, Minnesota: an update. Kidney Int. 2006;69(4):760‒764. https://doi.org/10.1038/sj.ki.5000150

10. Romero V, Akpinar H, Assimos DG. Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Rev Urol. 2010 Spring;12(2‒3):e86‒96. PMCID: PMC2931286

11. Scales CD, Smith AC, Hanley JM, Saigal CS, Urologic Diseases in America Project. Prevalence of kidney stones in the United States. EurUrol. 2012;62(1):160‒165. https://doi.org/10.1016/j.eururo.2012.03.052

12. Turney BW, Reynard JM, Noble JG, Keoghane SR. Trends in urological stone disease. BJU Int. 2012;109(7):1082–1087. https://doi.org/10.1111/j.1464-410X.2011.10495.x

13. Apolihin O.I., Sivkov A.V., Komarova V.A., Prosyannikov M.Yu., Golovanov S.A., Kazachenko A.V., Nikushina A.A., Shaderkina V.A. Urolithiasis in the Russian Federation (2005‒2016). Experimental and clinical urology. 2018;(4):4‒14. (in Russ.). eLIBRARY ID: 36802629

14. Gadzhiev N.K., Brovkin S.S., Grigor’ev V.E., Dmitriev V.V., Malkhasyan V.A., Shkarupa D.D., Pisarev A.V., Mazurenko D.A., Obidnyak V.M., Orlov I.N., Popov S.V., Tagirov N.S., Petrov S.V. Metaphylaxis of urolithiasis: a new view, a modern approach, mobile implementation. Urology. 2017;(1):124‒129. (in Russ.). https://dx.doi.org/10.18565/urol.2017.1.124-129

15. Brown MT, Bussell JK. Medication Adherence: WHO Cares? Mayo Clin Proc. 2011;86(4):304–314. https://dx.doi.org/10.4065/mcp.2010.0575

16. Rees J, Abrahams M, Doble A, Cooper A. Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/ chronic pelvic pain syndrome: a consensus guideline. Prostatitis Expert Reference Group (PERG). BJU Int. 2015;116(4):509‒525. https://dx.doi.org/10.1111/bju.13101

17. Polackwich AS, Shoskes DA. Chronic prostatitis/chronic pelvic pain syndrome: a review of evaluation and therapy. Prostate Cancer Prostatic Dis. 2016;19(2):132‒138. https://dx.doi.org/10.1038/pcan.2016.8

18. Bozhedomov V.A. Modern possibilities of treatment of chronic prostatitis. Andrology and genital surgery. 2016;17(3):10‒22. https://doi.org/10.17650/2070-9781-2016-17-3-10-22

19. Berry SJ, Coffey DS, Walsh PC, Ewing LLJ. The development of human benign prostatic hyperplasia with age. Urology. 1984;132(3):474‒479. https://doi.org/10.1016/s0022-5347(17)49698-4

20. Jespen JV, Bruskewitz RC. Comprehensive patient evaluation for benign prostate hyperplasia. Urology. 1998;51(suppl.4A):13–18. https://doi.org/10.1016/s0090-4295(98)00050-8

21. Huh JS, Kim YJ, Kim SD. Prevalence of Benign Prostatic Hyperplasia on Jeju Island: Analysis from a Cross-sectional Community-based Survey. World J Mens Health. 2012 Aug;30(2):131‒137. https://doi.org/10.5534/wjmh.2012.30.2.131

22. Prosyannikov M.Yu. Medical and economic efficiency of a standardized program for the diagnosis and treatment of benign prostatic hyperplasia [dissertation]. Moscow; 2016. (in Russ.). Available at: https://www.dissercat.com/content/ mediko-ekonomicheskaya-effektivnost-standartizirovannoiprogrammy- diagnostiki-i-lecheniya-do Accessed January 20, 2020.

23. Madersbacher S, Lackner J, Brössner C, Röhlich M, Stancik I, Willinger M, Schatzl G, Prostate Study Group of the Austrian Society of Urology. Reoperation, myocardial infarction and mortality aer transurethral and open prostatectomy: a nation-wide, long-term analysis of 23,123 cases. EurUrol. 2005;47(4):499‒504. https://doi.org/10.1016/j.eururo.2004.12.010

24. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2016. Cancer J. Clin. 2016;66(1):7–30. https://doi.org/10.3322/caac.21332

25. Kaprin A.D., Starinsky V.V., Petrova G V. Malignant neoplasms in Russia in 2016 (morbidity and mortality). Moscow: Moscow scientific research oncological Institute. P. A. Herzen “‒ branch of the Federal state budgetary institution “National medical research radiological center” of the Ministry of health of Russia; 2018. (in Russ.).

26. Carlsson S, Nilsson AE, Schumacher MS, Jonsson MN, Volz DS, Steineck G, Wiklund PN. Surgery-related complications in 1253 robot-assisted and 485 open retropubic radical prostatectomies at the Karolinska University Hospital, Sweden. Urology. 2010;75(5):1092‒1097. https://doi.org/10.1016/j.urology.2009.09.075

27. Ficarra V, Novara G, Artibani W, Cestari A, Galfano A, Graefen M, Guazzoni G, Guillonneau B, Menon M, Montorsi F, Patel V, Rassweiler J, Van Poppel H. Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies. EurUrol. 2009;55(5):1037‒1063. https://doi.org/10.1016/j.eururo.2009.01.036

28. Rabbani F, Yunis LH, Pinochet R, Nogueira L, Vora KC, Eastham JA, Guillonneau B, Laudone V, Scardino PT, Touijer K. Comprehensive standardized report of complications of retropubic and laparoscopic radical prostatectomy. EurUrol. 2010;57(3):371‒386. https://doi.org/10.1016/j.eururo.2009.11.034

29. Resnick MJ, Koyama T, Fan K-H, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Potosky AL, Stanford JL, Stroup AM, Van Horn RL, Penson DF. Long-term functional outcomes aer treatment for localized prostate cancer. N Engl J Med. 2013;368(5):436‒445. https://doi.org/10.1056/NEJMoa1209978

30. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol. 2001;165(4):1146‒1151. PMID:11257657

31. Teteneva T.A., Kurkin A.V., Bogdanova E.L. Preventive medicine in Russia: trends of development. Azimuth of scientific research: Economics and management. 2017;6(1):185‒187. (in Russ.). eLIBRARY ID: 29024924